Treatment with Sunitinib for Patients with Progressive Metastatic Pheochromocytomas and Sympathetic Paragangliomas

CONTEXT: Patients with progressive metastatic pheochromocytomas (PHEOs) or sympathetic paragangliomas (SPGLs) face a dismal prognosis. Current systemic therapies are limited. OBJECTIVES: The primary end point was progression-free survival determined by RECIST 1.1 criteria or positron emission tomogr...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Ayala-Ramirez, Montserrat, Chougnet, Cecile N., Habra, Mouhammed Amir, Palmer, J. Lynn, Leboulleux, Sophie, Cabanillas, Maria E., Caramella, Caroline, Anderson, Pete, Al Ghuzlan, Abir, Waguespack, Steven G., Deandreis, Desirée, Baudin, Eric, Jimenez, Camilo
Format: Artigo
Jezik:Inglês
Izdano: Endocrine Society 2012
Teme:
Endocrine Care
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3683800/
https://ncbi.nlm.nih.gov/pubmed/22965939
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2012-2356
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items